Browsing Tag
BASIS trial
2 posts
Can HYMPAVZI change hemophilia care for patients with inhibitors? Pfizer’s Phase 3 results signal a new standard
Pfizer’s HYMPAVZI showed 93% fewer bleeds in hemophilia patients with inhibitors. Explore how this subcutaneous treatment could redefine care standards.
FDA approves Pfizer’s HYMPAVZI for breakthrough hemophilia treatment
In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug…